• Arcus Biosciences’ third-quarter 2026 net loss narrowed 5% to $128 million; revenues fell 65% to $9 million year-over-year.
• Research and development expenses declined 17% year-over-year to $117 million, primarily due to lower late- and early-stage development activity.
• Cash, cash equivalents and marketable securities totaled $694 million at September 30; funding including October’s equity financing supports operations into 2029.
• Casdatifan’s Phase 3 PEAK-1 enrollment should finish within two to three months; the first-line PEAK-20 trial should begin by year-end 2026.
• Full-year 2026 GAAP revenues are expected to total $70 million to $75 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001724521-26-000056), on November 04, 2026, and is solely responsible for the information contained therein.